184 related articles for article (PubMed ID: 10069408)
41. How do you decide on hormone replacement therapy in women with risk of venous thromboembolism?
Lekovic D; Miljic P; Dmitrovic A; Thachil J
Blood Rev; 2017 May; 31(3):151-157. PubMed ID: 27998619
[TBL] [Abstract][Full Text] [Related]
42. Oral contraceptives and venous thromboembolism: a case-control study designed to minimize detection bias.
Realini JP; Encarnacion CE; Chintapalli KN; Rees CR
J Am Board Fam Pract; 1997; 10(5):315-21. PubMed ID: 9297655
[TBL] [Abstract][Full Text] [Related]
43. Risk of cardiovascular outcomes in users of estradiol/dydrogesterone or other HRT preparations.
Schneider C; Jick SS; Meier CR
Climacteric; 2009 Oct; 12(5):445-53. PubMed ID: 19565370
[TBL] [Abstract][Full Text] [Related]
44. Sex steroid hormones and breast cancer: is there a link with oral contraceptives and hormone replacement therapy?
Khoo SK; Chick P
Med J Aust; 1992 Jan; 156(2):124-32. PubMed ID: 1736053
[TBL] [Abstract][Full Text] [Related]
45. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users.
Cole JA; Norman H; Doherty M; Walker AM
Obstet Gynecol; 2007 Feb; 109(2 Pt 1):339-46. PubMed ID: 17267834
[TBL] [Abstract][Full Text] [Related]
46. Effect of NFE2L2 genetic polymorphism on the association between oral estrogen therapy and the risk of venous thromboembolism in postmenopausal women.
Bouligand J; Cabaret O; Canonico M; Verstuyft C; Dubert L; Becquemont L; Guiochon-Mantel A; Scarabin PY;
Clin Pharmacol Ther; 2011 Jan; 89(1):60-4. PubMed ID: 21107315
[TBL] [Abstract][Full Text] [Related]
47. Travel and the risk of symptomatic venous thromboembolism.
ten Wolde M; Kraaijenhagen RA; Schiereck J; Hagen PJ; Mathijssen JJ; Mac Gillavry MR; Koopman MM; Büller HR
Thromb Haemost; 2003 Mar; 89(3):499-505. PubMed ID: 12624634
[TBL] [Abstract][Full Text] [Related]
48. Postmenopausal hormone therapy and cardiovascular disease: an overview of main findings.
Canonico M; Straczek C; Oger E; Plu-Bureau G; Scarabin PY
Maturitas; 2006 Jul; 54(4):372-9. PubMed ID: 16730142
[TBL] [Abstract][Full Text] [Related]
49. Thrombophilia and the risk of thromboembolic events in women on oral contraceptives and hormone replacement therapy.
DeSancho MT; Dorff T; Rand JH
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):534-8. PubMed ID: 20581664
[TBL] [Abstract][Full Text] [Related]
50. Association of hormone replacement therapy to estrogen and progesterone receptor status in invasive breast carcinoma.
Chen WY; Hankinson SE; Schnitt SJ; Rosner BA; Holmes MD; Colditz GA
Cancer; 2004 Oct; 101(7):1490-500. PubMed ID: 15378477
[TBL] [Abstract][Full Text] [Related]
51. Myocardial infarction risk and hormone replacement: differences between products.
de Vries CS; Bromley SE; Farmer RD
Maturitas; 2006 Feb; 53(3):343-50. PubMed ID: 16040209
[TBL] [Abstract][Full Text] [Related]
52. [Vascular disease and hormonal treatment--epidemiology].
Vessey MP
Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):121-6. PubMed ID: 12280197
[TBL] [Abstract][Full Text] [Related]
53. The risk of recurrent venous thromboembolism in men and women.
Kyrle PA; Minar E; Bialonczyk C; Hirschl M; Weltermann A; Eichinger S
N Engl J Med; 2004 Jun; 350(25):2558-63. PubMed ID: 15201412
[TBL] [Abstract][Full Text] [Related]
54. [Hormone replacement therapy and cardio-vascular disease].
Lesiak M; Mariola RL; Podkowa N
Ginekol Pol; 2016; 87(1):59-64. PubMed ID: 27306470
[TBL] [Abstract][Full Text] [Related]
55. Progestogens and venous thromboembolism among postmenopausal women using hormone therapy.
Canonico M; Plu-Bureau G; Scarabin PY
Maturitas; 2011 Dec; 70(4):354-60. PubMed ID: 22024394
[TBL] [Abstract][Full Text] [Related]
56. The hormone replacement therapy (HRT) of menopause: focus on cardiovascular implications.
Denti L
Acta Biomed; 2010; 81 Suppl 1():73-6. PubMed ID: 20518194
[TBL] [Abstract][Full Text] [Related]
57. Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climacteric Study.
Sidelmann JJ; Jespersen J; Andersen LF; Skouby SO;
BJOG; 2003 Jun; 110(6):541-7. PubMed ID: 12798469
[TBL] [Abstract][Full Text] [Related]
58. Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe.
Stahlberg C; Pedersen AT; Lynge E; Andersen ZJ; Keiding N; Hundrup YA; Obel EB; Ottesen B
Int J Cancer; 2004 May; 109(5):721-7. PubMed ID: 14999781
[TBL] [Abstract][Full Text] [Related]
59. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women.
Olié V; Plu-Bureau G; Conard J; Horellou MH; Canonico M; Scarabin PY
Menopause; 2011 May; 18(5):488-93. PubMed ID: 21178641
[TBL] [Abstract][Full Text] [Related]
60. Oral contraceptives and hormone replacement therapy: How strong a risk factor for venous thromboembolism?
Skeith L; Le Gal G; Rodger MA
Thromb Res; 2021 Jun; 202():134-138. PubMed ID: 33836493
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
